Special Issue "Advances in Breast Cancer Research: From Biology to Pathology"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 31 August 2022.

Special Issue Editors

Prof. Dr. Reiner Strick
E-Mail Website
Guest Editor
Department of Gynecology, University Hospital Erlangen, Laboratory for Molecular Medicine, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany
Interests: tumor signaling; primary cells; cancer-associated fibroblasts; endogenous retroelements; innate immunity; 3D cell-migration
Dr. Ramona Erber
E-Mail Website
Guest Editor
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany
Interests: breast pathology; breast cancer; molecular subtyping; predictive biomarker; targeted therapy; gynecopathology

Special Issue Information

Dear Colleagues,

Breast cancer represents histological and molecular tumor subtypes, including luminal, basal, claudin-low, HER2-enriched, and unclassified subtypes stemming from different cellular origins and/or somatic changes, which are essential for the diagnosis and prediction of patient survival and therapy. Understanding the biology of non-neoplastic breast parenchyma as well as breast cancer will lead to better understandings of carcinogenesis and metastases, where both involve essential interaction with the tumor immune microenvironment. Uniting both the biological and pathological contexts of breast cancer will enable us to identify further targets for the development of more precise therapies in the future.

We are pleased to invite you to submit research papers, reviews, communications, etc., for this Special Issue of Cancers, “Advances in Breast Cancer Research: from Biology to Pathology”. Cancers encourages authors to publish experimental and theoretical results in as much detail as possible, which also include studies showing meaningful but negative results. We invite high-quality articles including basic, translational, and clinical studies on breast normal and tumor biology and pathology.

This Special Issue aims to strengthen interdisciplinary networking between molecular and cellular biology and pathology in order to accelerate translational research for breast cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • biology of non-neoplastic breast parenchyma and pathology of breast cancer;
  • histological and molecular tumor subtypes, prognosis and therapy;
  • tumor immune microenvironment including extracellular matrix of breast and breast cancer along with immune cell interactions;
  • primary normal and cancer cells including cancer-associated fibroblasts (CAFs) and adipose stem cells ;
  • plasticity from epithelial to mesenchymal (EMT) or amoeboid (EAT) cell types;
  • biomarkers and their regulation, including epigenetics;
  • structural cell changes and biophysics of breast cell migration.

We look forward to receiving your contributions.

Prof. Dr. Reiner Strick
Dr. Ramona Erber
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • ductal and lobular
  • triple negative
  • luminal
  • cancer associated fibroblast (CAF)
  • histology
  • steroid hormone receptors
  • HER2/neu
  • BRCA
  • prognostic factors
  • predictive biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
Cancers 2022, 14(2), 307; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14020307 - 08 Jan 2022
Viewed by 181
Breast cancer constitutes the most common malignant neoplasm in women around the world. Approximately 12% of patients are diagnosed with metastatic stage, and between 5 and 30% of early or locally advanced BC patients will relapse, making it an incurable disease. PD-L1 ligation [...] Read more.
Breast cancer constitutes the most common malignant neoplasm in women around the world. Approximately 12% of patients are diagnosed with metastatic stage, and between 5 and 30% of early or locally advanced BC patients will relapse, making it an incurable disease. PD-L1 ligation is an immune inhibitory molecule of the activation of T cells, playing a relevant role in numerous types of malignant tumors, including BC. The objective of the present review is to analyze the role of PD-L1 as a biomarker in the different BC subtypes, adding clinical trials with immune checkpoint inhibitors and their applicable results. Diverse trials using immunotherapy with anti-PD-1/PD-L1 in BC, as well as prospective or retrospective cohort studies about PD-L1 in BC, were included. Despite divergent results in the reviewed studies, PD-L1 seems to be correlated with worse prognosis in the hormone receptor positive subtype. Immune checkpoints inhibitors targeting the PD-1/PD-L1 axis have achieved great response rates in TNBC patients, especially in combination with chemotherapy, making immunotherapy a new treatment option in this scenario. However, the utility of PD-L1 as a predictive biomarker in the rest of BC subtypes remains unclear. In addition, predictive differences have been found in response to immunotherapy depending on the stage of the tumor disease. Therefore, a better understanding of tumor microenvironment, as well as identifying new potential biomarkers or combined index scores, is necessary in order to make a better selection of the subgroups of BC patients who will derive benefit from immune checkpoint inhibitors. Full article
(This article belongs to the Special Issue Advances in Breast Cancer Research: From Biology to Pathology)
Show Figures

Figure 1

Back to TopTop